SCHEMBL5401800

SCHEMBL5401800

FC(F)(F)c1ccc(/C=C/c2nc(CCl)cs2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 5/20 0.44
HDAC6 Q9UBN7 5/20 0.44
AHR P35869 1/20 0.43
PTGS1 P23219 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
ERBB2 P04626 6/20 0.39
NQO2 P16083 1/20 0.39
HIF1A Q16665 1/20 0.38
EPAS1 Q99814 1/20 0.38
CYP1A2 P05177 1/20 0.37
PTGER3 P43115 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5401803 1.00 HDAC1 (0.44) HDAC1HDAC6AHRPTGS1HDAC3
SCHEMBL5042873 0.82 HDAC1 (0.42) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL5045008 0.82 HDAC1 (0.42) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL5042874 0.82 HDAC1 (0.42) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL5045006 0.82 HDAC1 (0.42) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL5757647 0.80 HDAC1 (0.58) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL5757650 0.80 HDAC1 (0.58) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL24112057 0.80 MPL (0.41) HDAC1HDAC6
SCHEMBL5040848 0.80 HDAC1 (0.40) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL28478098 0.80 MPL (0.41) HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7259262-B2 Arylazole derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-08-21 US disclosed
CN-1867567-A 2-' (E) -2- (phenyl) vinyl-4- (arylalkoxy) -oxazole or-thiazole compounds as HER-2 tyrosine kinase inhibitors and their use in the treatment of cancer HOFFMANN LA ROCHE (CH) 2006-11-22 CN disclosed
EP-1680417-A1 1-'(E)-2-(PHENYL)ETHENYL-4-(ARYLALKOXY)-OXAZOLE OR -THIAZOLE COMPOUNDS AS HER-2 TYROSINE KINASES INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2006-07-19 EP disclosed
US-20050124670-A1 Novel arylazole derivatives, their manufacture and use as pharmaceutical agents F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2005-06-09 US disclosed
WO-2005040158-A1 1-′(E)-2-(PHENYL) ETHENYL-4-(ARYLALKOXY)-OXAZOLE OR - THIAZOLE COMPOUNDS AS HER-2 TYROSINE KINASES INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER F. HOFFMANN - LA ROCHE AG (CH) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124670-A1 Novel arylazole derivatives, their manufacture and use as pharmaceutical agents CYP3A43, CYP3A5, CYP1A1 HDAC1 269/4885HDAC6 277/4885AHR 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.